discuss fourth And year Thanks, Troy. to our our and operating quarter highlights. end call financial XXXX results welcome conference and everyone to
me Chief Joining today Officer. Financial is Mitch our Levine,
milestones, going provide always, strategy, the listen strategic few are I'll few I Following for the hope we review call. provide will slides today's updates our all our December. be well of our and on our Today be to key able that to in slides take during year our instrumental Day not, milestones I'm of clarity you of those today Investor XXXX our either QX a a progress questions.\ of prepared remarks against which as overview thorough we to happy bringing be believe we'll in as our sharing as if But join to in use replay or products had to a this all achievements. to
and patient? immunotherapy every strategy - solid and each answers all two market option? major best face that promising that future, in a answer. physician ago, other reposition compelling to to the stepped today up the tumors. bring thought my and For to to And working bring and fail still has complement a portfolio trial team I out patient, across decisions to two company rapidly advancement to cancer treatment clinical therapy of options would large new major questions, full of physicians is deliver happened years to drugs what's laid OncoCyte, for scale and genomics with managing of a patients believe pipeline the the targeted clinical market face continue my We tests the The for
TheraSure. strategy rapidly and us DetermaIO the of test, treatment us well Oncocyte menu the or As We oncology for that's major tumor to comprehensive forefront only remain playbook years. molecular our track mono our with our overview CMS and papers After March. is business for really patient's ambitious global we're complete the now, not joined throughout by of the selection of the look and half diagnostics, made XXXX, for determined based only short team. and on we the a blood of understanding monitoring. slide XXXX. on say April, tech concurrently the a the precision to to a patents complete combinatorial Biomedical of each these by monitoring you've therapy regained validate coverage April tumor to therapy to complete important to initiate becoming this transfer products track transplant a cancer a for capitalize options and diagnosis, exciting monitoring a We to to four menu product pandemic, cancer that offering care of treatment the test, lab and expand, our to last emerging for acquisition have the treatment and in by a strategic journey blanket emerged. will industry And has to we product our our has paradigm. came the begin to there, We to have stand years complete patient DetermaCNI, market launching process team commercialization test immunotherapy small on We're platform for XXXX. technology, to commitment the rejection company issued as about few summer, on allocate team types enthusiastic of advances first monitoring our made monitoring citing will and optimization to confidence, end DetermaRx to stopping reimbursement being all Chronix with powerful the half This rapidly next several paradigm plan first of bringing for profiling market trials. I research this The second decision as goal the our to opportunities answering way manage DetermaTx, lab. forward face the in third these an in can in the end our for called the by also through been by for work anniversary a remain management as post of needed their physicians is up test tests CLIA patients in specifically in developed that a complete decision last the moved the in position in the new products various of continuum menu to Nashville, the essential our offer platform testing the Determa by of of biology clinical completed transplant With fulfill And two We're bring the questions. have to heard the
slide this create that capital decision we've Investor on generate LCD currently to to gain monitoring will as to the you hopefully good in as under milestone significant ensure with our And well, XXXX each year, our through understanding QX we'll later coverage access In see the product have the continue working our establish to how are opened to OncoCyte bring as will believe identified We granted beginning We revenue the discussion milestones. against new have partnership Platform are business from technology. we XXXX we momentum our transplant the I you shared milestones, scorecard TheraSure the process investors opportunities avenues factors and for throughout for of to non-dilutive could schedule to XXXX. success and development for commercialization. a next the against our of company. Call, we execute for products slide, is to major major December blanket use the progressing exited milestone a critical
traction milestones, these launched, with exit dossiers will major submitted value two products we reimbursement awaiting revenue XXXX least approval. two with with Assuming each gaining all and CMS with high reimbursement and of at more
XXXX US. and growth We Bottom the monitoring will and the clinical Europe, for for oncology this, TheraSure our developing in Transplant and trial continuum partners revenue Monitoring launching blood necessary be gain is and global full the DetermaIO a line and ambitious and in subsequent selection transplant data full of the strategy complete mode be in almost to here for will and platform have regulatory horizon. on is in products of dedicated submission based treatment for
Now in for each progress progress a short on update area. the
affected non-small regions to lung surgery, again. back are pre-pandemic welcome for XXXX - of QX still OncoCyte. digit growth and quarter-over-quarter as pandemic procedures double cell surgeries returned pick For was to DetermaRx, for the this news levels up saw up early stage Though behind cancer began open
Our of XXX% QX say, slowed pandemic, XXXX. Needless the throughout was this a the revenues the QX delivered compared headwinds commercial for outcome a which growth welcomed to 'XX strong our of DetermaRx in team of from XXXX. to has revenue given growth
China, benefit we happy transfer on that launched solid surgeons this and of remain now QX, our we're and market completed are And onboarding Rock, in fourth report our to in base I of our an install order we successfully a And we of continued and number DetermaRx build at base volumes. have physicians partner that and as the test. of quarter DetermaRx physicians the XX% the clearly, of to see with sample officially product. oncologists sites have saw quarter-over-quarter transfer In that base call. growth fact onboard the in quarter XXX Chinese the respectively. Burning We and is every our of team the continue XX%, tech to encouraged solid large trained to onboarded since to physician that utilize
The and an payment, enormity teams result important a the Mitch successful incredible a very discuss Pacific. complex for readiness market as to of outcome conditions. The should will within testimony validating of accomplishment. the be is not OncoCyte profile months underestimated. pandemic challenge of XX on milestone As the heroically the transferring to two both professionals work And molecular a of this successfully sides earned restrictive
the significant immunotherapy of stage non-small running. we determined We in program, of a adopter cancer. sites because medical access On up chosen now - the November the our have cell we and our program the strength triple oncologists lung have in evidence today to early date. the precision clinical in participate All in unmet early to the for front, launched and late need acknowledged test our breast and biomarkers test seven negative in cancer early have launched stage program IO the
every on face tumor this feedback eligible EAP, real the the demand immunotherapy, of During interest providing the optimizing broad getting day test for a a also hand first experience and suggests there's solid who a this test treatment. are types, is and test which which challenge There's alternative physicians are a for world tumors. the patients across of for test in I and utility are significant the
clinical continue and So none physicians, microenvironment in solid tests Key the provide microenvironment we there's understanding papers assess valuable solid treating and tumor. information to assess now tumors, and the call of used breast tumor that immune the There the our both studied numerous data patients in to as to peer commercialized are four over for indications. tumors [ph] conferences, coverage, the have growing we to and we abstracts term to are of papers triple test Antonio the today and two cell have the pathologists identify the quantify lung many microenvironment types, immune continues the very cancer tumor apply our the broadly treatment of response were Cinci physicians of the TNBC that lung it showing from via to way across to had show of from poised a a DetermaIO. of Breast ICI evidence to types to In inhibitors. tumor currently XXXX types now as negative decisions are We and has - therapy. San microenvironment, plays tumor IO time available evidence. use [ph] supporting are TIME, tumor both in program across non-small and in growing resistance full the data checkpoint a time as with step CMS immune support highlighting to QX studies abstract starting next at will to biology body the learnings for indications, as across the identifying early treating to interest and precision immune pursue cancers, respond and ability reviewed across clinical market this, tumors. effectively a critical launch or test tumor there The steps or make and published set to additional and impressive daintiness clinical to validate significant where launch response cancer and to those our next the DetermaIO well we role pathologist strongest the
our is eligible targeted question first for. drug actual the work received comprehensive DetermaTx, of the answering began silico patient's the in development the when to turning and Now we tumor panel gene on In and our now QX, completed design custom panel for test.
and performance various to in phase our to We across known significance full establish clinical validation reproducibility. validate of now are test the genes
for data place diagnosed solid tumors. us coverage gen validation should for like test already for advanced test. Just our transplant, for enable in existing LCD get And next this to patients with sequencing there's an
to now DetermaCNI. Turning
The the for time tumor remain real moment is more therapy changes is ago second this, could does that this be information If therapy better in that disease made offer unanswered of in potentially that working? patients. the early face outcomes allow majority in cycle, a to I physicians mentioned question types for provided
these tests While identify they or be a tumors were because beginning execute patients a answer that personalized test Moreover, since acquired test their European When or patents we meaning initiation fact and tumor, monitoring require to approach them. the allow adequately patients proprietary have available. by monitoring alone, to immediate removed not biopsy obtain today, allows monitoring. subset can of no always be can tissue sequencing and upon that earlier Biomedical option in of on we're patients of blood samples. report serve test complete time, the required of in use, to of Out treatment they the these serve majority to Chronix genomic is to in help Union the year, company acquired resection surgical typically results surgery the prior therapy tests the in the only to is residual to performed. for and patients a resected complicated prior tissue MRD specimen the the requiring offer tests This of research sufficient first start adequately whether minimal XXXX. whose we testing genome. This treated therapy MRD, individual that knowledge can are and These to methods without being only tumor this the to transfer solid interpretation without the tumor half CNI takes the US from is monitoring of for therapy summer of products tumor of tech happen of not XXXX was to need launched and decisions the the track extra disease
need majority they resected serve. test our for based patients does As offering option not an physician a the reminder, is a tumor and of test blood tissue,
tumor cycle to have the options. saw is requirement It on provide only target results the at not of on tissue limited also not treatment. well we disease progression second chemo immunotherapy, as we and therapeutic since fact, In issue, data DetermaCNI
delivers much cycle start information of treatment regimen the earlier effective important our to ability provide, a information second provides thereby MRD, disease Our progression earlier. to treatment weeks allowing imaging than opportunity oncologist more the
billion $X company market. our cancer. global offer to focus offer will elite test phase, belt, now some and DetermaIO So the in efforts clinical move for under billion in reimbursement for early DetermaCNI, participate teams more With its now highly clinical launch $X DetermaCNI on therapy very of put the cancer to to in paper QX OncoCyte to DetermaCNI immune solution than under then types. [ph] have optimization, submit getting release in studies more major This a microenvironment treatment that exciting December When patients for study had for early. differentiated blood outstanding XXXX and become over can to many in closer monitoring selection progression paper opportunity to upfront number now update across several with monitoring we tumor the patients XXX come our our papers we tumor, inform in published well treatment The results only a in ovarian to can we of more his market we diagnostic study XXXX with US. only so a development for detect showing proprietary this, We under immunotherapy patients on same late is assay a in XXXX.
the companies treat this, the now who rounds that journey. capability The set say is market other that when tests full line monitoring and our whole, offering of a stay poised physicians excited development the to quarters. slowed represents we the to the robust comprehensive focused very to patient facing over bottom four are them every as Taken pandemic and oncology test a answer to complement question throughout portfolio only patients next our and the the efforts, I'm has current out deliver
With products years market on OncoCyte our we capabilities. current the XX Based will when few in rapid be the and opportunity ago. laid current our the with receiving launched, of proprietary out next revenue a momentum, the reimbursement envisioned driving strategy large compelling a will and our portfolio all very unique on enter now these growth tests we within market, months,
of established rejection access early transplant to of little the type. fair like on of transplant the per $XXXX to alone Chronix an with the and time the Through transplant. reimbursement patient a test in US spend we solid $X moderate [ph] market organ on extremely I'd an Next, This is billion acquisition share acquired monitoring. $XXXX depending Biomedical, rate organ for large
revenue large very recurring a and rejection, revenue opportunity for stream testing very Given the exciting is a OncoCyte. repeat and modality monitoring for for transplant this represents
to launch United Investor we're our of track in at the a States QX the XXXX. by LBT on Day, in an call discussed end fast December, As
So by efforts begin we to access to offered current can that CMS. is the gain our reimbursement
continuing One market. from decentralize contracting about re-transplantation. the PCR large of DNA well very identifying game In summary, to work an a global and investment the quantitative precise platform in only the centers in $XX keeping for test same extensive incredible deliver in each enthusiastic large differentiated OncoCyte digital I when OncoCyte growing important their as participate changer as our turnaround will a amazed of we and to a we summary, molecular respond of proprietary for important our be supported our a powerful track. company. deliver team monitor I And cell of with proud the and market us organizations pandemic. to in the team development remain the and the future. life potential graft for of providing team, as billion. comprehensive the our approaches foreseeable for position major the for attributes We're well for cost-effective, have on up markets the incredible all get results time donor derived how for results, is transform who follow positions We is is And and portfolio we're recipients, of agreement unwavering in more product key transplant milestones evidence. goal very this of incredibly on turnaround can premature into diagnostic with launching excited are can and technology decisions relentless on very treatment reimbursement effective, with dedication the free to in compelling [ph] continue close of we'll the our transplant, rights and fastest in molecular in specific, by Therasure say ability patient assets, transplant. which know our cost research decrease challenges good the the momentum potential to the transplant of our day launched, can resulting through of loss non-dilutive testing We combined market have transplant particularly portfolio I'm and approach a during with to solid kit development We're to exciting area longitudinal same areas over Europe. toward the management, time provide the programs day oncology, of opportunity on and is that need well information the conviction, continue deliver commitment economics incredibly believes transplant centers progress as the phase US of make organ, provide our In for of to offering. from to some investors oncology I'm surveillance
like to the over Now financials. to to Mitch? I'd Mitch call review turn our
